Across TCGA pan-cancer cohorts, MIR4796 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR4796’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MIR4796 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR4796 is over-expressed in tumor.
LIHC are the cancer types where MIR4796 tumor–normal differential expression is most reproducible.